We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Consensus Estimate for revenues is pegged at $3.60 billion, while the same for earnings is pinned at $0.57 per share.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Factors to Consider
Viatris reports its financial results in five segments— Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ) and Greater China.
Growth in Developed Markets, driven by strong new product performance and other generics, is likely to have boosted the top line.
Growth in Europe is anticipated to have been driven by contributions from new products and strong generics performance in key countries, including France.
The generic business in North America has likely benefited from complex products such as Breyna and Wixela as well as lisdexamfetamine.
The Zacks Consensus Estimate for revenues from Developed Markets is pinned at $2.2 billion.
Emerging Markets, too, have likely witnessed growth on the back of the expansion of its cardiovascular portfolio in certain Latin American countries and strength in other regions. The Zacks Consensus Estimate for revenues from this geography is pegged at $539 million.
Sales in JANZ have likely grown, driven by the launch of new products in Australia and the volume growth of promoted brands in Japan. The Zacks Consensus Estimate for revenues from the JANZ markets is pinned at $366 million.
Sales in Greater China might have seen an increase as a result of strong demand across multiple channels in China, including e-commerce, retail and hospitals. The Zacks Consensus Estimate for revenues from this geography is pegged at $553 million.
Viatris also reports revenues under two divisions (in terms of product category) — brands and generics.
Brand business makes up the majority of the company’s portfolio. Brand performance is likely to have benefited from the expansion of its cardiovascular portfolio in certain Latin American countries and strong growth in Europe and Greater China. Generic growth has likely been driven by strength in the broader European portfolio, complex products in North America and strong volume performance across the JANZ region.
Operating expenses might have risen during the quarter due to SG&A investments in the eye care franchise, new product launches and progress in key R&D programs.
VTRS’ Share Price Performance
Viatris’ shares have lost 13.2% in the past year compared with the industry’s decline of 15.8%.
Image Source: Zacks Investment Research
VTRS’ Mixed Earnings Surprise History
The company’s earnings beat estimates in two of the trailing four quarters and missed in the other two, delivering an average surprise of 0.33%. In the last reported quarter, VTRS beat on earnings by 10.29%.
What Our Model Predicts for Viatris
Our proven model does not conclusively predict an earnings beat for Viatris this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: VTRS has an Earnings ESP of -3.51% as the Zacks Consensus Estimate is pegged at 57 cents and the Most Accurate Estimate stands at 55 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
PCRX beat earnings estimates in two of the trailing four quarters, met once and missed in the other, delivering an average surprise of 7.13%. Shares of PCRX have surged 55.3% in the past three months.
Mirum Pharmaceuticals, Inc. (MIRM - Free Report) has an Earnings ESP of +24.63% and a Zacks Rank #2 at present.
Shares of MIRM have surged 20.6% in the past three months. MIRM is scheduled to report fourth-quarter results on Feb. 26.
Viking Therapeutics (VKTX - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank #3 at present.
Viking Therapeutics beat on earnings in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 4.15%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What's in the Cards for Viatris Stock This Q4 Earnings?
Viatris (VTRS - Free Report) , a global healthcare company, is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, 2025.
The Zacks Consensus Estimate for revenues is pegged at $3.60 billion, while the same for earnings is pinned at $0.57 per share.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Factors to Consider
Viatris reports its financial results in five segments— Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ) and Greater China.
Growth in Developed Markets, driven by strong new product performance and other generics, is likely to have boosted the top line.
Growth in Europe is anticipated to have been driven by contributions from new products and strong generics performance in key countries, including France.
The generic business in North America has likely benefited from complex products such as Breyna and Wixela as well as lisdexamfetamine.
The Zacks Consensus Estimate for revenues from Developed Markets is pinned at $2.2 billion.
Emerging Markets, too, have likely witnessed growth on the back of the expansion of its cardiovascular portfolio in certain Latin American countries and strength in other regions. The Zacks Consensus Estimate for revenues from this geography is pegged at $539 million.
Sales in JANZ have likely grown, driven by the launch of new products in Australia and the volume growth of promoted brands in Japan. The Zacks Consensus Estimate for revenues from the JANZ markets is pinned at $366 million.
Sales in Greater China might have seen an increase as a result of strong demand across multiple channels in China, including e-commerce, retail and hospitals. The Zacks Consensus Estimate for revenues from this geography is pegged at $553 million.
Viatris also reports revenues under two divisions (in terms of product category) — brands and generics.
Brand business makes up the majority of the company’s portfolio. Brand performance is likely to have benefited from the expansion of its cardiovascular portfolio in certain Latin American countries and strong growth in Europe and Greater China. Generic growth has likely been driven by strength in the broader European portfolio, complex products in North America and strong volume performance across the JANZ region.
Operating expenses might have risen during the quarter due to SG&A investments in the eye care franchise, new product launches and progress in key R&D programs.
VTRS’ Share Price Performance
Viatris’ shares have lost 13.2% in the past year compared with the industry’s decline of 15.8%.
Image Source: Zacks Investment Research
VTRS’ Mixed Earnings Surprise History
The company’s earnings beat estimates in two of the trailing four quarters and missed in the other two, delivering an average surprise of 0.33%. In the last reported quarter, VTRS beat on earnings by 10.29%.
What Our Model Predicts for Viatris
Our proven model does not conclusively predict an earnings beat for Viatris this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: VTRS has an Earnings ESP of -3.51% as the Zacks Consensus Estimate is pegged at 57 cents and the Most Accurate Estimate stands at 55 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Viatris Inc. Price, Consensus and EPS Surprise
Viatris Inc. price-consensus-eps-surprise-chart | Viatris Inc. Quote
Stocks to Consider
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around.
Pacira BioSciences, Inc. (PCRX - Free Report) has an Earnings ESP of +2.77% and a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
PCRX beat earnings estimates in two of the trailing four quarters, met once and missed in the other, delivering an average surprise of 7.13%. Shares of PCRX have surged 55.3% in the past three months.
Mirum Pharmaceuticals, Inc. (MIRM - Free Report) has an Earnings ESP of +24.63% and a Zacks Rank #2 at present.
Shares of MIRM have surged 20.6% in the past three months. MIRM is scheduled to report fourth-quarter results on Feb. 26.
Viking Therapeutics (VKTX - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank #3 at present.
Viking Therapeutics beat on earnings in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 4.15%.